Use of SLURP-1 compositions for treating schizophrenia

ABSTRACT

Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders. Also disclosed are compositions and methods for the treatment or prevention of skin pathologies. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. Antibodies generated against SLURP-1 and related proteins are also included.

RELATED APPLICATIONS

This application claims priority to U.S. Ser. No. 60/463,418, filed Apr.16, 2003, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates generally to compositions and methods for thetreatment or prevention of neurological disorders and skin pathologiesas well as for the modulation of acetylcholine receptor activity.

BACKGROUND OF THE INVENTION

The Ly-6/uPAR superfamily of receptors and secreted proteins contains acarboxy-terminal consensus sequence motif CCXXXXCN (SEQ ID NO:1) and oneor several repeats of the Ly-6/uPAR domain, which is defined by adistinct disulfide bonding pattern between eight or ten cysteineresidues (See Ploug et al., J. Biol. Chem., 268, 17539–17546 (1993);Ploug and Ellis, FEBS Lett., 349, 163–168 (1994); Casey et al., Blood,84, 1151–1156 (1994)).

The superfamily can be classified into two subfamilies on the basis ofthe presence or absence of a GPI-anchoring signal sequence (See Adermannet al., Protein Sci., 8, 810–819 (1999)). GPI-anchored Ly-6/uPARreceptor proteins include the retinoic acid-induced gene E (RIG-E, orhuman Ly-6E), the E48 antigen (human Ly-6D); Ly-6H; the PSCA; CD59 orprotectin; Lynx1 and uPAR (See Shan et al., J. Immununol., 160, 197–208(1998); Brakenhoff et al., J. Cell Biol., 129, 1677–1689 (1995); Horieet al., Genomics, 53, 365–368 (1998); Reiter et al., Proc. Natl Acad.Sci. USA, 95, 1735–1740 (1998); Tone et al., J. Mol. Biol., 227, 971–976(1992)). The E48 gene is known to be expressed in human keratinocytes,but not in lymphocytes, and it modulates desmosomal cell-cell adhesionof keratinocytes (Brakenhoff et al., J. Cell Biol., 129, 1677–1689(1995); Schrijvers et al., Exp. Cell. Res., 196, 264–269 (1991)). Theurokinase-type plasminogen activator receptor (uPAR) interacts indynamic association with integrins and initiates signaling events thatalter cell adhesion, migration, proliferation and differentiation (SeeBlasi and Carmeliet, Nat. Rev. Mol. Cell. Biol., 3, 932–943 (2002)).uPAR is a distant Ly-6/uPAR family member and, contrary to othermembers, it contains three contiguous copies of the Ly-6/uPAR domain.Differential cleavage of these domains regulates the multiple functionsof uPAR (See Palfree, Immunol. Today, 12, 170 (1991); Montuori, et al.,J. Biol. Chem., 277, 46932–46939 (2002)).

The second subfamily, which has a Ly-6/uPAR domain but no GPI-anchoringsignal sequence includes SLURP-1 and SLURP-2 (See Adermann et al.,Protein Sci., 8, 810–819 (1999); Tsuji et al., Genomics, 81, 26–33(2003)). Mutations in the gene encoding SLURP-1 have been implicated inMal de Meleda (MdM), as the MdM gene is located in a cluster of Ly-6genes on chromosome 8q24.3 (See Fischer et al., Eur. J. Hum. Genet., 6,542–547 (1998); Fischer et al., Hum. Mol. Genet., 10, 875–880 (2001);Eckl et al, Hum. Genet., 112, 50–56 (2003); Ward et al., J. Invest.Dermatol., 120, 96–98 (2003)).

SUMMARY OF THE INVENTION

The present invention provides methods for treating a neurologicaldisorder in a subject by administering an effective amount of SLURP-1 ora related protein to a subject suffering from the neurological disorder.

The present invention also provides methods for preventing or delayingthe onset of a neurological disorder in a subject by administering aneffective amount of SLURP-1 or a related protein to a subject at risk ofdeveloping or suffering from the neurological disorder.

Also provided are methods of providing neuroprotection to a subject byadministering an effective amount of SLURP-1 or a related proteins tothe subject where the neuroprotection prevents a neurological disordercaused by dysfunction of an acetylcholine receptor.

The present invention additionally provides methods for treating a skinpathology caused by dysfunction of an acetylcholine receptor expressedin the skin by administering an effective amount of SLURP-1 or a relatedprotein to a subject suffering from the skin pathology.

The present invention also provides methods for preventing or delayingthe onset of a skin pathology caused by dysfunction of an acetylcholinereceptor expressed in the skin by administering an effective amount ofSLURP-1 or a related protein to a subject at risk of developing orsuffering from the skin pathology.

Also provided are compositions including an effective amount of SLURP-1,a SLURP-1 mimetic, or a combination thereof and a carrier, where thecomposition modulates the function of an alpha 7 nicotinic acetylcholinereceptor or of a related protein. In one preferred embodiment, thecomposition is provided in a kit.

The invention also provides methods for modulating the activity of anacetylcholine receptor by contacting the acetylcholine receptor with aneffective amount of SLURP-1, where the effective amount of SLURP-1 isfrom about 1.0 pM to about 10 μM. In one preferred embodiment,modulation of the acetylcholine receptor restores the proper function ofthe acetylcholine receptor.

The present invention further provides methods of screening for amodulator of acetylcholine receptor activity by a) exposing a firstacetylcholine receptor with a candidate compound and measuring theactivity of the first acetylcholine receptor following the exposure, b)exposing a second acetylcholine receptor with an effective amount ofSLURP-1 or a related compound and measuring the activity of the secondacetylcholine receptor following the exposure, and c) comparing theactivity of the first acetylcholine receptor following the firstexposure to the activity of the second acetylcholine receptor followingthe exposure with SLURP-1 or a related compound. In such methods, if theactivity of the first acetylcholine receptor is similar to the activityof the second acetylcholine receptor, then the candidate compound is amodulator of acetylcholine receptor activity.

In preferred embodiments of the invention, the neurological disorder,that is treated and/or prevented, can be a pathology caused bydysfunction of an acetylcholine receptor. For example, the neurologicaldisorder can include pain, neuropathic pain, schizophrenia, cognitiveimpairments, Alzheimer's disease, and Parkinson's disease. Likewise, theskin pathology, that is treated and/or prevented, can include Mal deMeleda, wound healing, and psoriasis.

In a preferred embodiments of the invention, the acetylcholine receptoris a nicotinic acetylcholine receptor. Specifically, the nicotinicacetylcholine receptor can be an alpha 7 nicotinic acetylcholinereceptor or an alpha 7 nicotinic acetylcholine receptor-related protein.

In some embodiments, SLURP-1 is administered to the subject in a matureform. As used herein, the mature form of SLURP-1 includes amino acids23–103 of SLURP-1.

The present invention also provides methods of treating a neurologicaldisorder caused by the dysfunction of the alpha 7 nicotinicacetylcholine receptor by administering a composition containing aneffective amount of SLURP-1, or SLURP-1 mimetic or a combination thereofand a carrier to a subject suffering from the neurological disorder.

Also provided are methods of preventing or delaying the onset of aneurological disorder caused by the dysfunction of the alpha 7 nicotinicacetylcholine receptor by administering a composition of the presentinvention to a subject at risk of developing or suffering from theneurological disorder.

The present invention further provides methods of treating a skinpathology caused by the dysfunction of an alpha 7 nicotinicacetylcholine receptor expressed in the skin by administering acomposition containing an effective amount of SLURP-1, or SLURP-1mimetic or a combination thereof and a carrier to a subject sufferingfrom the skin pathology.

Likewise, the present invention also provides methods of preventing ordelaying the onset of a skin pathology caused by the dysfunction of analpha 7 nicotinic acetylcholine receptor expressed in the skin byadministering a composition of the present invention to a subject atrisk of developing or suffering from the skin pathology.

The present invention provides a antibody with high specific bindingaffinity to SLURP-1. The antibodies of the invention can be monoclonal,polyclonal or humanized.

In various embodiments of the invention, an effective amount of SLURP-1can be from about 1.0 pM to about 10 μM or form a solution contactingthe acetylcholine receptor at about 1.0 pM to about 10 μM. The effectiveamount of SLURP-1 can be administered orally, intravenously,intraperitoneally, intranasally, or intramuscularly. Administration ofSLURP-1 can also include the administering an expression vector capableof expressing the SLURP-1 protein into the subject. Preferably, thesubject receiving SLURP-1 is a mammal. More preferably, the subject is ahuman.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In the case of conflict, the presentspecification, including definitions, will control. In addition, thematerials, methods, and examples are illustrative only and are notintended to be limiting.

Other features and advantages of the invention will be apparent from thefollowing detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic of a recombinant SLURP-1 construct tagged withHA-tag and myc-tag FIGS. 1B and 1C are corresponding photographs ofimmunoblots showing that the signal sequence of SLURP-1 is cleavedduring processing and showing that SLURP-1 is not glycosylated,respectively.

FIGS. 2A and 2B are photographs of immunoblots showing the purificationof SLURP-1.

FIG. 3A is a schematic representation and FIG. 3B is the correspondingthree-dimensional model showing the structural homology between SLURP-1,members of the Ly-6/uPAR family and various snake venom toxins.

FIG. 4 is a schematic showing the homology comparisons between membersof the Ly-6/uPAR family and various snake venom toxins.

FIG. 5A is an electrophysiological recording and FIGS. 5B and 5C arecorresponding bar and line graphs showing that SLURP-1 modulates theactivity of acetylcholine receptors.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based in part on the ability of SLURP-1 tomodulate acetylcholine receptor activity. SLURP-1 is a 9 kDa proteinencoded by the ARS B gene. The amino acid sequence of SLURP-1 has 103amino acid residues:

(SEQ ID NO:2) MASRWAVQLLLVAAWSMGCGEALKCYTCKEPMTSASCRTITRCKPEDTACMTTLVTVEAEYPFNQSPVVTRSCSSSCVATDPDSIGAAHLIFCCFRDLCN SEL.

The present invention provides methods of treating, preventing ordelaying the onset of a neurological disorder or a skin pathology aswell as methods of modulating the activity of an acetylcholine receptor.As described herein in Examples 1 and 2 infra, SLURP-1 contains a signalpeptide at amino acids 1–22 and is secreted by N-terminal signalcleavage in a non-glycosylated, mature form (amino acids 23–103 of SEQID NO:2).

SLURP-1 has been shown herein to interact with acetylcholine receptorsand modulates their activity. For example, SLURP-1 enhanced theamplitude of the acetylcholine-evoked macroscopic currents in aconcentration-dependent manner. Specifically, SLURP-1 (at aconcentration of 200 pM) increased the amplitude of theacetylcholine-evoked macroscopic currents by 421±130% (n=6), and 20 nMSLURP-1 enhanced the amplitude by 1214±550% (n=4). See, Example 4,infra. Moreover, SLURP-1 induced an increase in both current amplitudeand sensitivity to acetylcholine as well as an increase in the Hillcoefficient. Because the application of SLURP-1 did not evoke currentsin the absence of acetylcholine, SLURP-1 does not function as a ligandor as a neurotransmitter. Rather, SLURP-1 modulates acetylcholinereceptor function in the presence of its natural ligand, whichdemonstrates that SLURP-1 acts as a positive allosteric effector atacetylcholine receptors. This finding is further supported by theincreased acetylcholine sensitivity and increased apparent cooperativitythat are hallmarks of allosteric effectors (See Changeux and Edelstein,Curr. Opin. Neurobiol., 11, 369–377 (2001)).

The present invention also includes methods of modulating epidermalcalcium homeostasis and keratinocyte proliferation and differentiation.SLURP-1 is closely related to the subfamily of single-domain snake andfrog cytotoxins, i.e. a-bungarotoxin (Bgtx) and a-cobratoxin (Cbtx).See, Example 3, infra. This high degree of structural homology betweenSLURP-1 and these snake neurotoxins indicates that SLURP-1 likelyinteracts with ion channels, the muscle and neuronal subtypes of thenicotinic acetylcholine receptor, and both muscarinic and nicotinicacetylcholine receptors that are expressed in keratinocytes (See Grandoand Horton, Curr. Opin. Dermatol., 4, 262–268 (1997); Grando, J. Invest.Dermatol. Symp. Proc., 2, 41–48 (1997)). Epidermal nicotinicacetylcholine receptors are involved in regulating cell adhesion,motility of epidermal keratinocytes and wound healing (See et al., J.Invest. Dermatol., 105, 774–781 (1995); Jacobi et al., Am. J. Pathol.,161, 97–104 (2002)).

These SLURP-1 interactions are comparable to the action of Lynx1. Lynx1has been shown to interact with neuronal nicotinic acetylcholinereceptors in the central nervous system where it modulates the cellularcalcium permeability (See Miwa et al., Neuron, 23, 105–114 (1999)).Calcium has an established role in the homeostasis of mammalian skin andmodulates keratinocyte proliferation and differentiation (See Menon etal., J. Invest. Dermatol., 84, 508–512 (1985); Elias et al., J. Invest.Dermatol., 119, 1128–1136 (2002)). Moreover, the association between thekeratotic palmoplantar skin disorder, Mal de Meleda, and mutations inSLURP-1 indicate that alterationor mutation of secreted SLURP-1 proteincan also disrupt skin homeostasis. Further, acetylcholine signalingthrough alpha (a7) nicotinic acetylcholine receptor channels appears tobe functional in keratinocytes and essential for epidermal homeostasis.

The present invention also provides methods of modulating inflammatoryresponses (e.g., cutaneous inflammation). For example, TNF-a is apleiotropic proinflammatory cytokine that elicits a large number ofbiological effects, including inflammatory and immunoregulatoryresponses (See Kondo and Sauder, Eur. J. Immunol., 27, 1713–1718(1997)). TNF-a is known to be released from keratinocytes afterstimulation with lipopolysaccharide (LPS), ultraviolet (UV) light orwound healing and participates in cutaneous inflammation (See Kock etal., J. Exp. Med., 172, 1609–1614 (1990)). Acetylcholine inhibits therelease of TNF-a and other cytokines on primary macrophages, through amechanism dependent on bungarotoxin-sensitive receptors (See Borovikovaet al., Nature, 405, 458–462 (2000)). Moreover, the a7 nicotinicacetylcholine receptor subunit is required for inhibition of TNF-arelease by macrophages (See Wang et al., Nature, 421, 384–388 (2003)),and inactivation of this pathway can contribute to excessive systemicrelease of cytokines during endotoxaemia or other injury. Further, asMal de Meleda is characterized by a clinical phenotype with markedcutaneous inflammation and is due to absent or mutated SLURP-1, it islikely that SLURP-1 controls TNF-a release in dermal macrophages and inkeratinocytes by activation of nicotinic acetylcholine receptors,thereby reducing inflammation. Thus, SLURP-1 or alterations thereof(e.g., point mutations, deletions, etc.) can modify the secretion ofTNF-a from macrophages and can modify inflammatory responses.

The high degree of structural homology between SLURP-1 and thethree-fingered protein family combined with the ability of SLURP-1 tomodulate acetylcholine receptor activity, indicates that SLURP-1 is alsofunctionally homologous to the venom toxins. Thus, it is useful fortreating or preventing neurological disorders or skin pathologies,modulating epidermal calcium homeostasis and keratinocyte proliferationand differentiation, modulating the secretion of TNF-a and modulatinginflammatory responses.

Methods of Using SLURP-1 as a Neuromodulator

The present invention provides methods for treating neurologicaldisorders in a subject by administering an effective amount of SLURP-1or a SLURP-1 related protein to the subject suffering from theneurological disorder.

Also provided by, the present invention are methods for preventing ordelaying the onset of neurological disorders in a subject byadministering an effective amount of SLURP-1 or a related protein to thesubject suffering from the neurological disorder.

The present invention further provides methods of providingneuroprotection to a subject by administering an effective amount ofSLURP-1 or a related protein to the subject where the neuroprotectionprevents a neurological disorder caused by dysfunction of anacetylcholine receptor.

For example, the neurological disorder can include any a pathologycaused by dysfunction of an acetylcholine receptor. Such disordersinclude, but are not limited to pain, neuropathic pain, schizophrenia,cognitive impairments, Alzheimer's disease, and Parkinson's disease. Inone preferred embodiment, the acetylcholine receptor is a nicotinicacetylcholine receptor or a muscarinic acetylcholine receptor.Preferably, the nicotinic acetylcholine receptor is an alpha 7 (α7)nicotinic acetylcholine receptor or an alpha 7 nicotinic acetylcholinereceptor related protein.

In the methods and compositions of the invention, SLURP-1 has the aminoacid sequence of SEQ ID NO:2. In a preferred embodiment, SLURP-1 is in amature form. More preferably, the mature form of SLURP-1 includes aminoacids 23–103 of SLURP-1.

The terms “subject” or “patient” are well-recognized in the art, and,are used interchangeably herein to refer to a mammal, including dog,cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, mostpreferably, a human. In some embodiments, the subject is a subject inneed of treatment. However, in other embodiments, the subject can be anormal subject, e.g., a subject having no known or diagnosedneurological disorder, e.g., a neurological disorder-free subject.Alternatively, the subject has a known, diagnosed, or suspectedneurological disorder.

The terms “treating” or “preventing” are also art-recognized. As usedherein, there terms refer to inhibiting, reducing, ameliorating, orcuring a condition (such as a neurological disorder) for which suchtreatment is indicated. The progress of such treatment can be monitored,e.g., by any measures known in the art.

A compound or pharmaceutical composition of the invention (e.g.,SLURP-1, a SLURP-1 related protein, or any member of the secretedLy-6/uPAR family) can be administered to a subject in many of thewell-known methods currently used for the treatment of neurologicaldisorders. For example, for treatment of neurological disorders, acompound of the invention can be administered orally, intravenously,intraperitoneally, intranasally, or intramuscularly. The dose chosenshould be sufficient to constitute effective treatment but not so highas to cause unacceptable side effects. The state of the diseasecondition (e.g., the neurological disorder) and the health of thesubject/patient should preferably be closely monitored during and for areasonable period after administration. Administration can also includethe administration of an expression vector capable of expressing theSLURP-1 protein, the SLURP-1 related protein, or a member of thesecreted Ly-6/uPAR family into the subject/patient. Preferably, membersof the secreted Ly-6/uPAR family include but are not limited to, Lynx-1Isoform A, Lynx-1 Isoform B (SLURP-2) and RGTR-430.

The term “effective amount” well known in the art used herein. As itrefers to an amount effective to achieve a desired result, such aspreventing, treating, inhibiting, reducing, ameliorating, or curing. Inone embodiment, a compound or pharmaceutical composition of theinvention (e.g., SLURP-1, SLURP-1 related protein, or a member of thesecreted Ly-6/uPAR family) is administered in an effective amount ofabout 1.0 pM to about 10 μM. In other embodiments, the effective amountis about 10 pM to about 1 μM; about 1 pM to about 100 nM; preferablyabout 10 pM to about 10 nM; or more preferably about 100 pM to about 1nM.

As used herein a “SLURP-1 related protein” is a protein that displaysstructural homology to SLURP-1 (SEQ ID NO:2) or a mature form of SLURP-1(e.g., amino acids 23–103 of SEQ ID NO:2). In one embodiment, a SLURP-1related protein is about 75% homologous/identical to SLURP-1 or a matureform of SLURP-1. In other embodiments, a SLURP-1 related protein isabout 80% homologous/identical; about 85% homologous/identical;preferably about 90% homologous/identical; more preferably about 95%homologous/identical or most preferably about 99% homologous/identical.In a preferred embodiment, a SLURP-1 related protein functionalhomologous to SLURP-1 or a mature form of SLURP-1. A SLURP-1 relatedprotein can include but is not limited to members of the secretedLy-6/uPAR family (e.g., Lynx-1 Isoform A, Lynx-1 Isoform B (SLURP-2),RGTR-430, etc.)

Homology/Identity is typically measured using sequence analysis software(e.g., Sequence Analysis Software Package of the Genetics ComputerGroup, University of Wisconsin Biotechnology Center, 1710 UniversityAvenue, Madison, Wis. 53705). Similar amino acid sequences are alignedto obtain the maximum degree of homology (i.e., identity). To this end,it may be necessary to artificially introduce gaps into the sequence.Once the optimal alignment has been set up, the degree of homology(i.e., identity) is established by recording all of the positions inwhich the amino acids of both sequences are identical, relative to thetotal number of positions.

Similarity factors include similar size, shape and electrical charge.One particularly preferred method of determining amino acid similaritiesis the PAM25O matrix described in Dayhoff et al., 5 Atlas Of ProteinSequence And Structure 345–352 (1978 & Suppl.), incorporated byreference herein. A similarity score is first calculated as the sum ofthe aligned pairwise amino acid similarity scores. Insertions anddeletions are ignored for the purposes of percent homology and identity.Accordingly, gap penalties are not used in this calculation. The rawscore is then normalized by dividing it by the geometric mean of thescores of the candidate compound and the reference sequence. Thegeometric mean is the square root of the product of these scores. Thenormalized raw score is the percent homology.

Methods of Using SLURP-1 to Treat or Prevent Skin Pathologies

The present invention additionally provides methods for treating skinpathologies caused by dysfunction of an acetylcholine receptor expressedin the skin by administering an effective amount of SLURP-1 or a SLURP-1related protein to a subject suffering from the skin pathology.

Moreover, the present invention also provides methods for preventing ordelaying the onset of skin pathologies caused by dysfunction of anacetylcholine receptor expressed in the skin by administering aneffective amount of SLURP-1 or a SLURP-1 related protein to a subject atrisk of developing or suffering from the skin pathology.

Also provided herein are methods for modulating epidermal calciumhomeostasis by contacting the acetylcholine receptor with an effectiveamount of SLURP-1, where the effective amount of SLURP-1 is from about 1pM to about 10 μM.

The present invention further provides methods for modulatingkeratinocyte proliferation and differentiation by contacting theacetylcholine receptor with an effective amount of SLURP-1 or a SLURP-1related protein, where the effective amount is from about 1 pM to about10 μM.

The invention also provides methods for modulating the secretion ofTNF-a by contacting the acetylcholine receptor with an effective amountof SLURP-1 or a SLURP-1 related protein, where the effective amount isfrom about 1 pM to about 10 μM.

Moreover, the invention also provides methods for modulating aninflammatory response by contacting the acetylcholine receptor with aneffective amount of SLURP-1 or a SLURP-1 related protein, where theeffective amount of SLURP-1 is from about 1 pM to about 10 μM.

Preferably, the acetylcholine receptor is a nicotinic acetylcholinereceptor or a muscarinic acetylcholine receptor. For example, thenicotinic acetylcholine receptor is an alpha 7 nicotinic acetylcholinereceptor or an alpha 7 nicotinic acetylcholine receptor related protein.

In one embodiment, SLURP-1 that is administered to the subject has theamino acid sequence of SEQ ID NO:2. In one preferred embodiment, SLURP-1is in a mature form. Those skilled in the art will recognize that themature form of SLURP-1 includes amino acids 23–103 of SEQ ID NO:2.

Preferably, the subject is a mammal. More preferably, the subject is ahuman. The subject may be a subject in need of treatment, or the subjectcan be a normal subject, e.g., a subject having no known or diagnosedskin pathologies, e.g., a skin pathology-free subject. In otherembodiments, the subject has a known, diagnosed, or suspected skinpathology. The skin pathology may include but is not limited to, Mal deMeleda, wound healing or psoriasis. Those skilled in the art willrecognize that the methods and compositions disclosed herein can be usedto treat or prevent any skin pathology resulting from a dysfunction ofan acetylcholine receptor expressed in the skin.

A compound or pharmaceutical composition of the invention (e.g.,SLURP-1, a SLURP-1 related protein, or a member of the secretedLy-6/uPAR family) can be administered to a subject in many of thewell-known methods currently used for treatment of skin pathologies. Forexample, for treatment of skin pathologies, a compound of the inventioncan be administered orally, intravenously, intraperitoneally,intranasally, or intramuscularly. The dose chosen should be sufficientto constitute effective treatment but not so high as to causeunacceptable side effects. Selection of an appropriate dose is withinthe skill of those in the art. The state of the disease condition (e.g.,the skin pathology) and the health of the subject/patient shouldpreferably be closely monitored during and for a reasonable period afteradministration. Administration can also include the administration of anexpression vector capable of expressing the SLURP-1 protein, SLURP-1related protein, or a member of the secreted Ly-6/uPAR family into thesubject/patient. Suitable members of the secreted Ly-6/uPAR familyinclude, but are not limited to, Lynx-1 Isoform A, Lynx-1 Isoform B(SLURP-2) and RGTR-430.

For example, a compound or pharmaceutical composition of the invention(e.g., SLURP-1, SLURP-1 related protein, or a member of the secretedLy-6/uPAR family) is administered in an effective amount of about 1.0 pMto about 10 μM. In other embodiments, the effective amount is about 10pM to about 1 μM; about 1 pM to about 100 Mn; preferably about 10 pM toabout 10 nM; or a more preferably about 100 pM to about 1 nM.

Compositions of SLURP-1 to Treat or Prevent Neurological Disorders orSkin Pathologies

The present invention also provides compositions including an effectiveamount of SLURP-1, a SLURP-1 mimetic, a SLURP-1 related protein, or acombination thereof and a carrier, where the composition modulates thefunction of an alpha 7 nicotinic acetylcholine receptor or of a relatedprotein. In one preferred embodiment, the composition is provided aspart of a kit.

Likewise, the present invention also provides methods of treating aneurological disorder caused by the dysfunction of the alpha 7 nicotinicacetylcholine receptor by administering a composition of the presentinvention to the subject suffering from the neurological disorder.

Also provided are methods of preventing or delaying the onset of aneurological disorder caused by the dysfunction of the alpha 7 nicotinicacetylcholine receptor by administering a composition of the presentinvention to the subject at risk of developing or suffering from theneurological disorder.

The present invention further provides a method of treating a skinpathology caused by the dysfunction of an alpha 7 nicotinicacetylcholine receptor expressed in the skin by administering acomposition of the present invention to the subject suffering from theskin pathology.

Moreover, the present invention also provides a method of preventing ordelaying the onset of a skin pathology caused by the dysfunction of analpha 7 nicotinic acetylcholine receptor expressed in the skin byadministering a composition of the present invention to the subject atrisk of developing or suffering from the skin pathology.

The methods and compositions present invention also encompass SLURP-1peptide mimetics (peptidomimetics) SLURP-1 related protein peptidemimetics, and peptide mimetics of members of the secreted Ly-6/uPARfamily. Techniques for development of peptide mimetics are well known inthe art. (See for example, Navia and Peattie, Trends Pharm Sci 14:189–195, 1993; Olson et al, J Med Chem 36: 3039–3049 which areincorporated by reference). Specifically using the amino acid sequenceof SLURP-1, or SLURP-1 related protein, or members of the secretedLy-6/uPAR family, X-ray crystallography and nuclear magnetic resonancetechnology along with computerized molecular modeling, a pharmacophorehypothesis is developed and peptide mimetic compounds are made andtested in an assay system.

For example, the invention includes compounds or compositions of theinvention (e.g., SLURP-1 or a member of the secreted Ly-6/uPAR family inwhich one or more peptide bonds have been replaced with an alternativetype of covalent bond (a “peptide mimetic”), which is not susceptible tocleavage by peptidases. Where proteolytic degradation of the peptidesfollowing injection into the subject is a problem, replacement of aparticularly sensitive peptide bond with a noncleavable peptide mimeticrenders the resulting peptide more stable and thus more useful as atherapeutic. Such mimetics, and methods of incorporating them intopeptides, are well known in the art. Similarly, the replacement of anL-amino acid residue is a standard way of rendering the peptide lesssensitive to proteolysis. The molecular interactions of a peptidemimetic are similar to that of the naturally-occurring molecule.

The compounds, compositions or pharmaceutical compositions of theinvention (e.g., SLURP-1, SLURP-1 related protein, or a member of thesecreted Ly-6/uPAR family), and derivatives, fragments, analogs andhomologs thereof, can be incorporated into compositions suitable foradministration. Such compositions typically comprise the nucleic acidmolecule, or protein, and a pharmaceutically acceptable carrier. As usedherein, “carrier” or “pharmaceutically acceptable carrier” is intendedto include any and all solvents, dispersion media, coatings,antibacterial and antifungal agents, isotonic and absorption delayingagents, and the like, compatible with pharmaceutical administration.Suitable carriers are described in the most recent edition ofRemington's Pharmaceutical Sciences, a standard reference text in thefield, which is incorporated herein by reference. Preferred examples ofsuch carriers or diluents include, but are not limited to, water,saline, finger's solutions, dextrose solution, and 5% human serumalbumin. Liposomes and non-aqueous vehicles such as fixed oils may alsobe used. The use of such media and agents for pharmaceutically activesubstances is well known in the art. Except insofar as any conventionalmedia or agent is incompatible with the active compound, use thereof inthe compositions is contemplated. Supplementary active compounds canalso be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to becompatible with its intended route of administration. Examples of routesof administration include parenteral, e.g., intravenous, intradermal,subcutaneous, oral (e.g., inhalation), transdermal (topical),transmucosal, and rectal administration. Solutions or suspensions usedfor parenteral, intradermal, or subcutaneous application can include thefollowing components: a sterile diluent such as water for injection,saline solution, fixed oils, polyethylene glycols, glycerine, propyleneglycol or other synthetic solvents; antibacterial agents such as benzylalcohol or methyl parabens; antioxidants such as ascorbic acid or sodiumbisulfite; chelating agents such as ethylenediaminetetraacetic acid;buffers such as acetates, citrates or phosphates, and agents for theadjustment of tonicity such as sodium chloride or dextrose. The pH canbe adjusted with acids or bases, such as hydrochloric acid or sodiumhydroxide. The parenteral preparation can be enclosed in ampoules,disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterileaqueous solutions (where water soluble) or dispersions and sterilepowders for the extemporaneous preparation of sterile injectablesolutions or dispersion. For intravenous administration, suitablecarriers include physiological saline, bacteriostatic water, CremophorEL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In allcases, the composition must be sterile and should be fluid to the extentthat easy syringeability exists. It must be stable under the conditionsof manufacture and storage and must be preserved against thecontaminating action of microorganisms such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (for example, glycerol, propylene glycol, andliquid polyethylene glycol, and the like), and suitable mixturesthereof. The proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prevention of the action of microorganisms can be acetylcholineieved byvarious antibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In manycases, it will be preferable to include isotonic agents, for example,sugars, polyalcohols such as manitol, sorbitol, sodium chloride in thecomposition. Prolonged absorption of the injectable compositions can bebrought about by including in the composition an agent which delaysabsorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating a compoundor pharmaceutical composition of the invention (e.g., SLURP-1, a SLURP-1related protein, or a member of the secreted Ly-6/uPAR family) in therequired amount in an appropriate solvent with one or a combination ofingredients enumerated above, as required, followed by filteredsterilization. Generally, dispersions are prepared by incorporating theactive compound into a sterile vehicle that contains a basic dispersionmedium and the required other ingredients from those enumerated above.In the case of sterile powders for the preparation of sterile injectablesolutions, methods of preparation are vacuum drying and freeze-dryingthat yields a powder of the active ingredient plus any additionaldesired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an ediblecarrier. They can be enclosed in gelatin capsules or compressed intotablets. For the purpose of oral therapeutic administration, the activecompound can be incorporated with excipients and used in the form oftablets, troches, or capsules. Oral compositions can also be preparedusing a fluid carrier for use as a mouthwash, wherein the compound inthe fluid carrier is applied orally and swished and expectorated orswallowed. Pharmaceutically compatible binding agents, and/or adjuvantmaterials can be included as part of the composition. The tablets,pills, capsules, troches and the like can contain any of the followingingredients, or compounds of a similar nature: a binder such asmicrocrystalline cellulose, gum tragacanth or gelatin; an excipient suchas starch or lactose, a disintegrating agent such as alginic acid,Primogel, or corn starch; a lubricant such as magnesium stearate orSterotes; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in theform of an aerosol spray from pressured container or dispenser whichcontains a suitable propellant, e.g., a gas such as carbon dioxide, or anebulizer.

Systemic administration can also be by transmucosal or transdermalmeans. For transmucosal or transdermal administration, penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art, and include, forexample, for transmucosal administration, detergents, bile salts, andfusidic acid derivatives. Transmucosal administration can beaccomplished through the use of nasal sprays or suppositories. Fortransdermal administration, the active compounds are formulated intoointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g.,with conventional suppository bases such as cocoa butter and otherglycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers thatwill protect the compound against rapid elimination from the body, suchas a controlled release formulation, including implants andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid.Methods for preparation of such formulations will be apparent to thoseskilled in the art. The materials can also be obtained commercially fromAlza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions(including liposomes targeted to infected cells with monoclonalantibodies to viral antigens) can also be used as pharmaceuticallyacceptable carriers. These can be prepared according to methods known tothose skilled in the art, for example, as described in U.S. Pat. No.4,522,811, which is incorporated herein by reference in its entirety.

It is especially advantageous to formulate oral or parenteralcompositions in dosage unit form for ease of administration anduniformity of dosage. Dosage unit form, as used herein, refers tophysically discrete units suited as unitary dosages for the subject tobe treated; each unit containing a predetermined quantity of activecompound calculated to produce the desired therapeutic effect inassociation with the required pharmaceutical carrier. The specificationfor the dosage unit forms of the invention are dictated by and directlydependent on the unique characteristics of the active compound and theparticular therapeutic effect to be achieved.

The compositions of the invention can be included in a kit, container,pack, or dispenser together with instructions for administration.

Another aspect of the invention pertains to vectors, preferablyexpression vectors, containing a nucleic acid encoding an SLURP-1protein, a SLURP-1 related protein, or a protein from any member of thesecreted Ly-6/uPAR family, or derivatives, fragments, analogs orhomologs thereof. As used herein, the term “vector” refers to a nucleicacid molecule capable of transporting another nucleic acid to which ithas been linked. One type of vector is a “plasmid”, which refers to acircular double stranded DNA loop into which additional DNA segments canbe ligated. Another type of vector is a viral vector, wherein additionalDNA segments can be ligated into the viral genome. Certain vectors arecapable of autonomous replication in a host cell into which they areintroduced (e.g., bacterial vectors having a bacterial origin ofreplication and episomal mammalian vectors). Other vectors (e.g.,non-episomal mammalian vectors) are integrated into the genome of a hostcell upon introduction into the host cell, and thereby are replicatedalong with the host genome. Moreover, certain vectors are capable ofdirecting the expression of genes to which they are operatively-linked.Such vectors are referred to herein as “expression vectors”. In general,expression vectors of utility in recombinant DNA techniques are often inthe form of plasmids. In the present specification, “plasmid” and“vector” can be used interchangeably as the plasmid is the most commonlyused form of vector. However, the invention is intended to include suchother forms of expression vectors, such as viral vectors (e.g.,replication defective retroviruses, adenoviruses and adeno-associatedviruses), which serve equivalent functions.

The recombinant expression vectors of the invention can be designed forexpression of a SLURP-1 protein, a SLURP-1 related protein, or a proteinfrom any member of the secreted Ly-6/uPAR family in prokaryotic oreukaryotic cells. For example, the proteins can be expressed inbacterial cells such as Escherichia coli, insect cells (usingbaculovirus expression vectors) yeast cells or mammalian cells. Suitablehost cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY:METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).Alternatively, the recombinant expression vector can be transcribed andtranslated in vitro, for example using T7 promoter regulatory sequencesand T7 polymerase.

Methods of Using SLURP-1 to Modulate Acetylcholine Receptor Activity

The present invention also provides methods for modulating the activityof an acetylcholine receptor by contacting the acetylcholine receptorwith an effective amount of SLURP-1 or a SLURP-1 related protein, wherethe effective amount is from about 1 pM to about 10 μM. In a preferredembodiment, modulation of the acetylcholine receptor restores the properfunction of the acetylcholine receptor.

For example, the acetylcholine receptor is a nicotinic acetylcholinereceptor or a muscarinic acetylcholine receptor. Preferably, thenicotinic acetylcholine receptor is an alpha 7 nicotinic acetylcholinereceptor or an alpha 7 nicotinic acetylcholine receptor-related protein.

SLURP-1 has the amino acid sequence of SEQ ID NO:2. In one preferredembodiment, SLURP-1 is in a mature form. More preferably, the matureform of SLURP-1 includes amino acids 23–103 of SEQ ID NO:2.

The terms “modulate” or “modulating” are art-recognized. As used herein,thus refer to stimulating, inducing, upregulating, enhancing ordecreasing, inhibiting, reducing, repressing. As used herein, a“modulator” is a molecule which stimulates (i.e. induces, enhances orupregulates) or inhibits (i.e. reduces, represses or decreases) theactivity of an acetylcholine receptor.

Methods of Screening for Acetylcholine Receptor Activity Modulators

The present invention additionally provides a method of screening for amodulator of acetylcholine receptor activity by a) exposing a firstacetylcholine receptor with a candidate compound and measuring theactivity of the first acetylcholine receptor following the exposure, b)exposing a second acetylcholine receptor with an effective amount ofSLURP-1 or a related compound and measuring the activity of the secondacetylcholine receptor following the exposure, and c) comparing theactivity of the first acetylcholine receptor following the firstexposure to the activity of the second acetylcholine receptor followingthe exposure with SLURP-1 or a related compound. If the activity of thefirst acetylcholine receptor is similar to the activity of the secondacetylcholine receptor following exposure, then the candidate compoundis a modulator of acetylcholine receptor activity.

In one embodiment, the acetylcholine receptor is a nicotinicacetylcholine receptor or a muscarinic acetylcholine receptor.Preferably, the nicotinic acetylcholine receptor is an alpha 7 nicotinicacetylcholine receptor or an alpha 7 nicotinic acetylcholine receptorrelated protein.

SLURP-1 has the amino acid sequence of SEQ ID NO:2. In one preferredembodiment, SLURP-1 is in a mature form. The mature form of SLURP-1includes amino acids 23–103 of SEQ ID NO:2.

Typically, a compound of the invention (e.g., SLURP-1, a SLURP-1 relatedprotein, or a member of the secreted Ly-6/uPAR family) forms a solutionfor contacting the acetylcholine receptor in an effective amount ofabout 1.0 pM to about 10 μM. In other embodiments, the effective amountis about 10 pM to about 1 μM; about 1 pM to about 100 nM; preferably 10pM to about 10 nM; or more preferably 100 pM to about 1 nM.

Anti-SLURP Antibodies

Also provided by the present invention are antibodies having highspecific binding affinity to SLURP-1. The antibody can be, e.g.,monoclonal, polyclonal or humanized. For example, high specific bindingaffinity may be represented by a dissociation constant less than5.0×10⁻⁵ M. Preferably, the high specific binding affinity isrepresented by a dissociation constant less than 5.0×10⁻⁷ M. Morepreferably, the high specific binding affinity is represented by adissociation constant less than 5.0×10⁻⁹ M.

The term “antibody” as used herein refers to immunoglobulin moleculesand immunologically active portions of immunoglobulin (Ig) molecules,i.e., molecules that contain an antigen binding site that specificallybinds (immunoreacts with) an antigen. Such antibodies include, but arenot limited to, polyclonal, monoclonal, chimeric, single chain, F_(ab),F_(ab′) and F_((ab′)2) fragments, and an F_(ab) expression library. Ingeneral, an antibody molecule obtained from humans relates to any of theclasses IgG, IgM, IgA, IgE and IgD, which differ from one another by thenature of the heavy chain present in the molecule. Certain classes havesubclasses as well, such as IgG₁, IgG₂, and others. Furthermore, inhumans, the light chain may be a kappa chain or a lambda chain.Reference herein to antibodies includes a reference to all such classes,subclasses and types of human antibody species.

An isolated SLURP-1 protein, SLURP-1 related protein, or SLURP-1 peptidemimetic of the invention can serve as an antigen, or a portion orfragment thereof, and additionally can be used as an immunogen togenerate antibodies that immunospecifically bind the antigen, usingstandard techniques for polyclonal and monoclonal antibody preparation.The full-length protein can be used or, alternatively, the inventionprovides antigenic peptide fragments of the antigen for use asimmunogens. An antigenic peptide fragment comprises at least 6 aminoacid residues of the amino acid sequence of the full length protein, andencompasses an epitope thereof such that an antibody raised against thepeptide forms a specific immune complex with the full length protein orwith any fragment that contains the epitope. By epitope, reference ismade to an antigenic determinant of a polypeptide. Typically, epitopescontain hydrophilic amino acids such that the particular region of thepolypeptide is located on its surface and likely to be exposed in anaqueous based milieu. Preferably, the antigenic peptide comprises atleast 3 amino acid residues in a spatial conformation which is unique tothe epitope. Generally, the antigenic peptide comprises at least 5 aminoacid residues, or at least 10 amino acid residues, or at least 15 aminoacid residues, or at least 20 amino acid residues, or at least 30 aminoacid residues. Furthermore, antibodies to a SLURP-1 protein, SLURP-1related protein, or SLURP-1 peptide mimetic or fragments thereof canalso be raised against oligopeptides that include a conserved region.

Hydrophobicity analysis of a SLURP-1 protein, SLURP-1 related protein,or SLURP-1 peptide mimetic sequence will indicate which regions areparticularly hydrophilic and, therefore, are likely to encode surfaceresidues useful for targeting antibody production. As a means fortargeting antibody production, hydropathy plots showing regions ofhydrophilicity and hydrophobicity may be generated by any method wellknown in the art, including, for example, the Kyte Doolittle or the HoppWoods methods, either with or without Fourier transformation. See, e.g.,Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824–3828; Kyte andDoolittle 1982, J. Mol. Biol. 157: 105–142, each of which isincorporated herein by reference in its entirety. Antibodies that arespecific for one or more domains within an antigenic protein, orderivatives, fragments, analogs or homologs thereof, are also providedherein. A protein of the invention, or a derivative, fragment, analog,homolog or ortholog thereof, may be utilized as an immunogen in thegeneration of antibodies that immunospecifically bind these proteincomponents.

Various procedures known within the art may be used for the productionof polyclonal or monoclonal antibodies directed against a protein of theinvention, or against derivatives, fragments, analogs homologs ororthologs thereof (See for example, Antibodies: A Laboratory Manual,Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., incorporated herein by reference). Some of theseantibodies are discussed below.

For the production of polyclonal antibodies, various suitable hostanimals (e.g., rabbit, goat, mouse or other mammal) may be immunized byone or more injections with the native protein, a synthetic variantthereof, or a derivative of the foregoing. An appropriate immunogenicpreparation can contain, for example, the naturally occurringimmunogenic protein, a chemically synthesized polypeptide representingthe immunogenic protein, or a recombinantly expressed immunogenicprotein. Furthermore, the protein may be conjugated to a second proteinknown to be immunogenic in the mammal being immunized. Examples of suchimmunogenic proteins include but are not limited to keyhole limpethemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsininhibitor. The preparation can further include an adjuvant. Variousadjuvants used to increase the immunological response include, but arenot limited to, Freund's (complete and incomplete), mineral gels (e.g.,aluminum hydroxide), surface active substances (e.g., lysolecithin,pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol,etc.), adjuvants usable in humans such as Bacille Calmette-Guerin andCorynebacterium parvum, or similar immunostimulatory agents. Additionalexamples of adjuvants which can be employed include MPL-TDM adjuvant(monophosphoryl Lipid A, synthetic trehalose dicorynomycolate) and CpGdinucleotide motifs (See, Krieg, A. M. Biochim Biophys Acta1489(1):107–16, 1999). The polyclonal antibody molecules directedagainst the immunogenic protein can be isolated from the mammal (e.g.,from the blood) and further purified by well known techniques, such asaffinity chromatography using protein A or protein G, which provideprimarily the IgG fraction of immune serum. Subsequently, oralternatively, the specific antigen which is the target of theimmunoglobulin sought, or an epitope thereof, may be immobilized on acolumn to purify the immune specific antibody by immunoaffinitychromatography. Purification of immunoglobulins is discussed, forexample, by D. Wilkinson (The Scientist, published by The Scientist,Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25–28).

The term “monoclonal antibody” (MAb) or “monoclonal antibodycomposition”, as used herein, refers to a population of antibodymolecules that contain only one molecular species of antibody moleculeconsisting of a unique light chain gene product and a unique heavy chaingene product. In particular, the complementarity determining regions(CDRs) of the monoclonal antibody are identical in all the molecules ofthe population. MAbs thus contain an antigen binding site capable ofimmunoreacting with a particular epitope of the antigen characterized bya unique binding affinity for it. Monoclonal antibodies can be preparedusing hybridoma methods, such as those described by Kohler and Milstein,Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, orother appropriate host animal, is typically immunized with an immunizingagent to elicit lymphocytes that produce or are capable of producingantibodies that will specifically bind to the immunizing agent.Alternatively, the lymphocytes can be immunized in vitro.

The monoclonal antibodies can also be made by recombinant DNA methods,such as those described in U.S. Pat. No. 4,816,567. DNA encoding themonoclonal antibodies of the invention can be readily isolated andsequenced using conventional procedures (e.g., by using oligonucleotideprobes that are capable of binding specifically to genes encoding theheavy and light chains of murine antibodies). The hybridoma cells of theinvention serve as a preferred source of such DNA. Once isolated, theDNA can be placed into expression vectors, which are then transfectedinto host cells such as simian COS cells, Chinese hamster ovary (CHO)cells, or myeloma cells that do not otherwise produce immunoglobulinprotein, to obtain the synthesis of monoclonal antibodies in therecombinant host cells. The DNA also can be modified, for example, bysubstituting the coding sequence for human heavy and light chainconstant domains in place of the homologous murine sequences (U.S. Pat.No. 4,816,567; Morrison, Nature 368, 812–13 (1994)) or by covalentlyjoining to the immunoglobulin coding sequence all or part of the codingsequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulinpolypeptide can be substituted for the constant domains of an antibodyof the invention, or can be substituted for the variable domains of oneantigen-combining site of an antibody of the invention to create achimeric bivalent antibody.

The antibodies directed against the protein antigens of the inventioncan further comprise humanized antibodies or human antibodies. Theseantibodies are suitable for administration to humans without engenderingan immune response by the human against the administered immunoglobulin.Humanized forms of antibodies are chimeric immunoglobulins,immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′,F(ab′)₂ or other antigen-binding subsequences of antibodies) that areprincipally comprised of the sequence of a human immunoglobulin, andcontain minimal sequence derived from a non-human immunoglobulin.Humanization can be performed following the method of Winter andco-workers (See, Jones et al., Nature, 321:522–525 (1986); Riechmann etal., Nature, 332:323–327 (1988); Verhoeyen et al., Science,239:1534–1536 (1988)), by substituting rodent CDRs or CDR sequences forthe corresponding sequences of a human antibody. (See also U.S. Pat. No.5,225,539.) The humanized antibody optimally also will comprise at leasta portion of an immunoglobulin constant region (Fc), typically that of ahuman immunoglobulin (See, Jones et al., 1986; Riechmann et al., 1988;and Presta, Curr. Op. Struct. Biol., 2:593–596 (1992)).

The invention will be further described in the following examples, whichdo not limit the scope of the invention described in the claims.

EXAMPLES Example 1

To assess whether SLURP-1 is a secreted peptide and to determine thepresence of a putative cleavage site of the signal sequence, arecombinant protein SLURP-1 with an N-terminal haemaglutinin (HA) tagand a C-terminal myc tag was produced. Specifically, plasmids wereconstructed. Specifically, for expression in mammalian cells, the cDNAencoding for SLURP-1 was modified by PCR to add 5′HindIII and 3′XbaIrestriction sites at their termini with the following primers:

(SEQ ID NO:3) sense, 5′-AAGCTTGGAGCAATGGCCTCTCGCTGG and (SEQ ID NO:4)antisense, 5′-TCTAGAGAGTTCCGAGTTGCAGAGGTC.

The PCR fragments were purified from agarose gels and ligated intoHindIII- and XbaI-digested pBudCE4 (Invitrogen) to give the plasmidpBud-SLURP-1, which allowed addition of a C terminal myc tag fordetection by western analysis and His₆ tag for purification. To generatethe recombinant SLURP-1 protein with tags at both N- and C-termini, thecDNA encoding for SLURP-1 was amplified from pBud-SLURP-1 by PCR usingprimers containing 5′EcoRV and 3′BglII restriction sites at theirtermini and including the myc tag. The following primers were used:

sense, 5′-GAGATATCGGAGCAATGGCC-TCTCG (SEQ ID NO:5) and antisense,5′-AGAGATCTTCACAGATCCTCTT-CTGAGATG AGTTT. (SEQ ID NO:6)

The PCR fragments were purified from agarose gels and ligated intoEcoRV- and BglII-digested pCRUZ-HA (Santa Cruz), to generate pCSLURP-1,which allowed addition of an N-terminal haemagglutinin (HA) tag.

The resulting plasmids were then used to transform competent XL1-Bluecells. Single colonies were picked, and plasmid DNA was isolated andpurified using reagents from Qiagen according to the manufacturer'sinstructions. For expression in insect cells, the pBud-SLURP-1 plasmidwas digested by HindIII and EcoRV. The fragment corresponding to SLURP-1cDNA with a myc tag at C-terminus was purified from agarose gels andligated into HindIII- and XbaI-digested pIZ (Invitrogen), thusgenerating pIZ-SLURP-1, which encodes for the same protein aspBud-SLURP-1, including myc and His₆ tags. Correct insertion and inframe cloning of all plasmids was verified by sequencing.

HEK 293T cells (ATCC CRL-11268) were cultured in Dulbecco's modifiedEagle's medium supplemented with 10% fetal calf serum (Gibco), 2 mML-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin, at 37°C. in a 5% CO₂ humidified atmosphere. The cells were harvested bytrypsinization when ˜90% confluent and plated at split ratios of 1:5.Stable cell lines expressing SLURP-1 were generated by calcium phosphatetransfection of pBud-SLURP-1 as previously described (See, Jordan etal., Nucl. Acids Res., 24, 596–601 (1996)) and Zeocin selection. Clonalcell lines were isolated by the dilution method. Trichoplusia ni(HighFive, Invitrogen) cells were maintained at 27° C. in Express Five®SFM medium (Life Technologies). To generate stable cell lines, 10 μg ofpIZ-SLURP-1 was transfected in HighFive cells with Cellfectin™ accordingto the manufacturer's instructions. Zeocin was added 48 h later forselection. Clonal cell lines were isolated with cloning cylinders.

The produced recombinant protein SLURP-1 with an N-terminalhaemaglutinin (HA) tag and a C-terminal myc tag is shown in FIG. 1A.Following transient transfection of 293T cells with the construct,SLURP-1 was identified 48 h later in the culture medium byimmunoblotting with anti-myc antibodies (See, FIG. 1B). As shown in FIG.1B, immunoblotting with anti-HA antibodies did not indicate the presenceof SLURP-1 in the culture medium. These result show that the signalsequence of SLURP-1 is cleaved before secretion during intracellularprocessing.

Recombinant polyhistidine-tagged SLURP-1 was purified by a cobaltaffinity chromatography with Talon resin (Clontech). Specifically,recombinant SLURP-1 was purified using the His₆ tag from the culturemedium of stably transfected mammalian and insect cells, which werecultured for 3 days before the medium was harvested. After dialysisagainst buffer A (50 mM sodium phosphate; 300 mM NaCl; pH 7.4),supernatants were incubated with Talon resin (Clontech) and the nativebuffer protocol provided. After washing, the fusion protein was elutedwith buffer A containing 150 mM imidazole. The fractions containingSLURP-1 were either dialysed against buffer A or loaded on a BioRadBioPrepSE-100/17gel filtration chromatography column and eluted withbuffer A to obtain pure recombinant SLURP-1.

FIG. 2A shows the 293T-SLURP-1 stable cell line generated by calciumphosphate transfection and Zeocin selection. Culture medium wascollected after 72 h. His6-tagged SLURP-1 was purified from culturemedium with Talon resin. Fractions were loaded on a 15% SDS-PAGE.Proteins were revealed either by silver staining or immunoblotted withanti-myc antibody. Lane 1, input; lane 2, flow-through; lane 3, wash 1;lane 4, wash 2; lane 5, elution 1; lane 6, elution 2. The results in FIG2A show that most proteins did not bind the resin, and remained in theflowthrough fraction.

FIG. 2B shows silver stained SDS-PAGE (15% acrylamide) of recombinantSLURP-1 following purification with Talon resin and size exclusionchromatography. The results in FIG. 2B show that co-purified proteinswere eliminated by gel filtration (BioRad BioPrepSE-100/17) and purerecombinant SLURP-1 was obtained. The estimated final yield was about100 μg of protein per liter of culture medium.

Example 2

Since protein glycosylation can change biological properties and sinceSLURP-1 contains a putative N-glycosylation site on N64, partiallypurified SLURP-1 was produced in mammalian and insect cells wasincubated with N-glycosidase F, which hydrolyses N-glycan chains.Specifically, approximately 10 mg of myc-His6-tagged SLURP-1 partiallypurified either from insect or mammalian cells culture medium wasdiluted in a solution of 25 mM sodium phosphate (pH 7.0), 25 mM EDTA,and 0.15% SDS and then heated at 100° C. for 5 min. After the solutioncooled, 10% Nonidet P-40 and 0.6 U N-glycosidase F (Roche) were added(final detergent concentrations, 0.1% SDS and 0.5% Nonidet P-40) and themixture was incubated at 37° C. for 20 h. The reaction was stopped byadding SDS-PAGE sample buffer, followed by incubation at 100° C. for 5min. Samples were then loaded in 15% SDS-PAGE and revealed with silverstaining or western blotting with anti-myc antibody, using co-purifiedproteins as internal positive control for N-glycosidase F activity. Theshift in the migration in some of these co-purified proteins indicatedthe proper functioning of the enzyme. The arrow in FIG. 1C indicatesco-purified deglycosylated protein not present before N-glycosidasetreatment. The results in FIG. 1C show that N-glycosidase treatment didnot modify the migration of SLURP-1, indicating that SLURP-1 is notglycosylated.

Example 3

Because SLURP-1 is member of the Ly-6/αBgtx families, structuralanalysis studies were conducted to determine the similarity of SLURP-1to other proteins. FIG. 3A shows a phylogenetic tree of the Ly-6/αBgtxfamilies indicating the relationship between secreted snake toxins andthe GPI-anchored Ly-6/uPAR family. Phylogenetic tree calculation isbased on a sequence distance method and utilizes the neighbor joiningalgorithm (See, Saitou and Nei, Mol. Biol. Evol., 4, 406–425 (1987).FIG. 4 shows the comparison of domain constitution between members ofthe Ly-6/uPAR family and snake venom toxins. All of the proteins of thefamily share the same consensus domain. uPAR shares the same structurebut also contains three contiguous Ly-6/uPAR domains. The GPI anchorsignal sequence indicates cleavage site after addition of GPI moiety.The data in FIG. 3A and in FIG. 4 show that phylogenetic analysis basedon the SLURP-1 amino acid sequence reveals a close relationship to thesubfamily of single domain snake and frog cytotoxins, i.e.a-bungarotoxin. The data further shows that SLURP-1 is phylogeneticallymore closely related to snake toxins than it is to the mammalianGPI-anchored receptors.

To further analyze the structure of SLURP-1, a three dimensional modelwas generated. Specifically, three dimensional model of SLURP-1 wasbuilt by the computer program 3D-PSSM (See, Kelley et al., J. Mol.Biol., 299, 499–520 (2000)). 3D-PSSM (three-dimensionalposition-specific scoring matrix) uses structural alignments ofhomologous proteins of similar three-dimensional structure in thestructural classification of proteins (SCOP) database to obtain astructural equivalence of residues. These equivalences are used toextend multiply aligned sequences obtained by standard sequencesearches. The resulting large superfamily-based multiple alignment isconverted into a PSSM. Combined with secondary structure matching andsolvation potentials, 3D-PSSM can recognize structural and functionalrelationships between homologous proteins (See, Kelley et al., J. Mol.Biol., 299, 499–520 (2000)). FIG. 3B shows the comparison of the SLURP-1model (left) and the CD59 extracellular domain experimental NMRstructure (right, PDB code: 1ERG). SLURP-1 cysteines are colored inyellow, as disulfide bridges of the CD59 extracellular domain. The dataindicates the homologous disposition of CD59 disulfide bridges andSLURP-1 cysteines. Both proteins structurally adopt, or are predicted toadopt, the characteristic ‘three-finger’ appearance of snake proteins.N- and C-terminal ends of the molecules are labeled. Thethree-dimensional structure analysis of SLURP-1 in FIG. 3B shows thatSLURP-1 resembles the three-dimensional structure of other Ly-6 proteinsand three-fingered frog and snake venom toxins, i.e. CD59 anda-bungarotoxin.

Example 4

A study was performed to determine whether SLURP-1 interacts withnicotinic acetylcholine receptors and is functionally homologous to thevenom toxins. In the study, acetylcholine-elicited macroscopic currentresponses in control and SLURP-1-treated Xenopus oocytes expressingrecombinant human a7 nicotinic acetylcholine receptors were examined.

Specifically, X. laevis oocytes were isolated and prepared as describedpreviously (See, Bertrand et al., In: Methods in Neuroscience, Conn, M.(ed.). Academic Press, New York, Vol. 4, pp. 174–193 (1991)). Oocyteswere intranuclearly injected with 2 ng of human a7 cDNA and kept inseparate wells of a 96-well microtitre plate at 18° C. OR2 controlmedium consisted of 88 mM NaCl, 2.5 mM KCl, 10 mM HEPES, 1 mM MgCl₂, and2 mM CaCl₂, pH 7.4, adjusted with NaOH. Electrophysiology experimentswere carried out 2–4 days after cDNA injection. Electrophysiologicalrecordings were performed using a two-electrode voltage-clamp (GeneClampamplifier; Axon Instruments, Union City, Calif., USA); holding potentialwas—100 mV. Electrodes were pulled from borosilicate glass and contained3M KCl. Solution exchanges were performed by an automated system basedaround a liquid handling robot. Oocytes were continuously superfusedwith OR2 except during peptide incubation. Oocytes were maintained at18° C. during experiments. Dose-response curves were fit by the equationy=I_(max)*{1/(1+(EC₅₀/[Ach])^(n))}, where I_(max) is the maximalnormalized current amplitude, EC50 the half effective agonistconcentration, n the Hill coefficient and [Ach] the Acetylcholineconcentration.

Acetylcholine-evoked responses were measured before and after exposure(2.5–5 min) to highly purified SLURP-1. SLURP-1 enhanced the amplitudeof the Acetylcholine-evoked macroscopic currents in aconcentration-dependent manner. FIG. 5A shows current responses beforeand after 5 min exposure to 20 nM SLURP-1. Currents were activated by a2s application of 100 mM Acetylcholine. The results in FIG. 5A show thatat a concentration of 200 pM, SLURP-1 increased the amplitude of theAcetylcholine-evoked macroscopic currents by 421±130% (n=6), and 20 nMSLURP-1 enhanced the amplitude by 1214±550% (n=4), compared withcontrol. As shown in FIG. 5B, the dose-response curve indicates thatSLURP-1 potentiates a7 nicotinic acetylcholine receptor homopentamers,since the EC₅₀ was 175 μM acetylcholine for the controls and dropped to68 μM Acetylcholine after SLURP-1 treatment. FIG. 5C shows that 200 pMSLURP-1 shifted the Acetylcholine dose response curve (closed squares)to the left and increased Emax (solid circles). EC50 was 178 μM forcontrol and 68 μM after 2.5 min exposure to SLURP-1 (200 pM). n=6 foreach data point. The effects of SLURP-1 on the Acetylcholinedose-response curve indicate that 200 pM causes an increase in bothcurrent amplitude and sensitivity to Acetylcholine as well as anincrease in the Hill coefficient. Application of SLURP-1 did not evokecurrents in the absence of Acetylcholine. Thus, SLURP-1 functions not asa ligand or neurotransmitter, but modulates receptor function in thepresence of its natural ligand in a manner consistent with an allostericmode of action.

Example 5

To further characterize the electrophysiology of SLURP-1 activity onacetylcholine receptors and identify the site of interaction,chimeric-subunits are constructed from α7 and subunits that are notpotentiated by SLURP-1 and express them in X. laevis oocytes. Thespecific amino acid residues implicated in the action of SLURP-1 areidentified using α7 subunits containing single point mutations.Electrophysiological studies are extended to keratinocytes in cultureand other cell types expressing the acetylcholine receptor target ofSLURP-1. The impact of SLURP-1 on keratinocyte differentiation isstudied in organotypic skin cultures.

The interaction of SLURP-1 with acetylcholine receptors is characterizedat the molecular level. The effects of the mutated SLURP-1 proteins iscompared to those of native SLURP-1 on homomeric and heteromericacetylcholine receptors. Identification of residues essential forinteraction of SLURP-1 with its target(s) facilitates the design ofmolecules either mimicking or antagonizing the effect of SLURP-1 sinceinteraction of three finger toxins with their target often involves onlya few amino acids, either clustered or spread along the primarystructure of the proteins (See, Kini, Clin Exp Pharmacol Physiol 29(9):815–22 (2002)).

To determine the in situ localization of SLURP-1 and its transcripts, insitu hybridization studies are carried out on human biopsies usinganti-SLURP-1 antibodies. Monoclonal and polyclonal anti-SLURP-1antibodies can be generated to specific domains (i.e. internal domain)of SLURP-1 for these and additional studies. These studies willcomplement immunohistochemical studies localizing SLURP-1 in variousepithelia (See, Mastrangeli and Donini, Eur J Dermatol 13(6): 560–70(2003)). These studies will identify altered expression of SLURP-1 incertain pathologies, e.g., dermatological disorders.

To determine the effective of SLURP-1 on gene expression in vivo, humanbiopsies and SLURP-1 transgenic mice are subjected to microarrayanalysis. The expression of SLURP-1 in these transgenic mice is underthe control of keratin 14 promoter (basal layer expression). Thesestudies allow for the identification of the exact physiological effectsof SLURP-1 in vivo.

Example 6

To determine the activity of other secreted Ly-6/uPAR family members(Lynx-1 Isoform A, Lynx-1 Isoform B and RGTR-430), Ly-6/uPAR familymember recombinant proteins expressing c-myc and His₆ tags are generatedas described (See, Example 1, supra, and Chimineti et al., Hum Mol Genet12(22): 3017–24 (2003)). These Ly-6/uPAR family member recombinantproteins are purified to apparent homogeneity in two steps byimmobilized metal affinity chromatography and gel filtration asdescribed (See, Example 1, supra; Chimineti et al., Hum Mol Genet12(22): 3017–24 (2003); Ibanez et al., Neuron 33(6): 893–903 (2002)).Further, monoclonal and polyclonal antibodies are generated to specificsecreted Ly-6/uPAR family member proteins. These antibodies can begenerated to specific domains. Alternatively, since homology amongsecreted Ly-6/uPAR family member proteins is low, rabbits can beimmunized with complete proteins or GST-fusion proteins.

Various tissues have been analyzed to determine the expression of genesencoding the secreted Ly-6/uPAR family members using RT-PCR. Studiesshow that transcripts for SLURP-1, RGTR-430 and Lynx-1 Isoform B arehighly expressed in the epidermis and in normal human keratinocytes inculture; while the expression of Lynx-1 transcript 3, coding for theGPI-anchored Isoform C, is much more ubiquitously expressed. Further,the effects of secreted Ly-6/uPAR family member proteins can be assessedon ligand-gated ion channels expressed in X. laevis oocytes to identifytheir action on acetylcholine receptor activity as described (See,Example 4, supra; Chimineti et al., Hum Mol Genet 12(22): 3017–24(2003).

OTHER EMBODIMENTS

While the invention has been described in conjunction with the detaileddescription thereof, the foregoing description is intended to illustrateand not limit the scope of the invention, which is defined by the scopeof the appended claims. Other aspects, advantages, and modifications arewithin the scope of the following claims.

1. A method for treating schizophrenia in a subject suffering therefrom,the method comprising administering to the subject an effective amountof a SLURP-1 polypeptide comprising the amino acid sequence of SEQ IDNO: 2, thereby treating schizophrenia in the subject.
 2. A method fortreating schizophrenia in a subject suffering therefrom, the methodcomprising administering to the subject an effective amount of a SLURP-1polypeptide comprising amino acids 23–103 of the amino acid sequence ofSEQ ID NO: 2, thereby treating schizophrenia in the subject.
 3. Themethod of claim 2, comprising administering to the subject an effectiveamount of a SLURP-1 polypeptide consisting of amino acids 23–103 of SEQID NO:
 2. 4. A method for treating schizophrenia in a subject sufferingtherefrom, the method comprising administering to the subject aneffective amount of a SLURP-1 polypeptide at least 95% identical to theamino acid sequence of SEQ ID NO:2 and wherein the polypeptide enhancesthe amplitude of acetylcholine-evoked macroscopic currents, therebytreating schizophrenia in the subject.
 5. The method of claim 4, whereinthe SLURP-1 polypeptide is at least 99% identical to the amino acidsequence of SEQ ID NO:2.
 6. The method of claim 1, 2, 3, 4 or 5 whereinthe effective amount of the SLURP-1 polypeptide is from about 1.0 pM toabout 10 μM.
 7. The method of claim 1, 2, 3, 4 or 5 wherein theeffective amount of the SLURP-1 polypeptide is administered to thesubject by a method selected from the group consisting of orally,intravenously, intraperitoneally, intranasally, and intramuscularly.